Novo Nordisk A Slash S
Novo Nordisk A/S, headquartered in Denmark (DK), is a global leader in the pharmaceutical industry, specialising in diabetes care, obesity management, and hormone replacement therapies. Founded in 1923, the company has achieved significant milestones, including the development of innovative insulin products and GLP-1 receptor agonists that have transformed diabetes treatment. With a strong presence in Europe, North America, and Asia, Novo Nordisk is renowned for its commitment to sustainability and patient-centric solutions. Its core products, such as insulin pens and diabetes management devices, are distinguished by their advanced technology and user-friendly design. As a pioneer in diabetes care, Novo Nordisk holds a prominent market position, consistently recognised for its contributions to improving patient outcomes and advancing healthcare globally.
DitchCarbon Score
How does Novo Nordisk A Slash S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novo Nordisk A Slash S's score of 57 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Novo Nordisk A Slash S's reported carbon emissions
In 2023, Novo Nordisk A/S reported total carbon emissions of approximately 3,831,000,000 kg CO2e. This figure includes 78,000,000 kg CO2e from Scope 1 emissions, 15,000,000 kg CO2e from Scope 2 emissions, and a significant 1,743,000,000 kg CO2e from Scope 3 emissions. The company has made substantial commitments to reduce its carbon footprint, aiming for net-zero emissions by 2045. Novo Nordisk has set ambitious targets to achieve a 100% reduction in Scope 1 and Scope 2 emissions by 2030, using 2018 as the base year. Additionally, the company is working with key suppliers—300 in total, representing two-thirds of its Scope 3 emissions—to establish greenhouse gas reduction targets by 2030. This commitment aligns with the Science Based Targets initiative (SBTi) and is consistent with the reductions necessary to limit global warming to 1.5°C. In summary, Novo Nordisk A/S is actively addressing its carbon emissions through significant reduction targets and a long-term commitment to sustainability, positioning itself as a leader in the pharmaceutical sector's response to climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 145,000,000 | 00,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novo Nordisk A Slash S is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
